Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of JNJ-73763989 in Renal Impairment
NCT04963738Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2021
- Primary completion
- Oct 2022
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of tomligisiran in Chronic Hepatitis B (CHB) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Plasma Concentration of JNJ-73763989. Started Sep 2021; status: completed.
02
Drugs
tomligisiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04963738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04963738.